Immune checkpoint inhibitor (ICI)-related inflammatory diseases, including polymyositis (PM) and dermatomyositis (DM), in patients suffering from neoplastic disorders represent a medical challenge. The treatment of these conditions has taken on new urgency due to the successful and broad development of cancer-directed immunological-based therapeutic strategies. While primary and secondary PM/DM phenotypes have been pathophysiologically characterized, a rational, stepwise approach to the treatment of patients with ICI-related disease is lacking. In the absence of high-quality evidence to guide clinical judgment, the available data must be critically assessed. In this literature review, we examine partially neglected immunological and clinical findings to obtain insights into the biological profiles of ICI-related PM/DM and potential treatment options. We show that differential diagnosis is essential to stratifying patients according to prognosis and therapeutic impact. Finally, we provide a comprehensive assessment of druggable targets and suggest a stepwise patient-oriented approach for the treatment of ICI-related PM/DM.

Immune Checkpoint Inhibitor-Related Myositis: From Biology to Bedside / Solimando, Antonio G; Crudele, Lucilla; Leone, Patrizia; Argentiero, Antonella; Guarascio, Matteo; Silvestris, Nicola; Vacca, Angelo; Racanelli, Vito. - In: INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. - ISSN 1422-0067. - 21:9(2020), pp. 305401-305413. [10.3390/ijms21093054]

Immune Checkpoint Inhibitor-Related Myositis: From Biology to Bedside

Racanelli, Vito
2020-01-01

Abstract

Immune checkpoint inhibitor (ICI)-related inflammatory diseases, including polymyositis (PM) and dermatomyositis (DM), in patients suffering from neoplastic disorders represent a medical challenge. The treatment of these conditions has taken on new urgency due to the successful and broad development of cancer-directed immunological-based therapeutic strategies. While primary and secondary PM/DM phenotypes have been pathophysiologically characterized, a rational, stepwise approach to the treatment of patients with ICI-related disease is lacking. In the absence of high-quality evidence to guide clinical judgment, the available data must be critically assessed. In this literature review, we examine partially neglected immunological and clinical findings to obtain insights into the biological profiles of ICI-related PM/DM and potential treatment options. We show that differential diagnosis is essential to stratifying patients according to prognosis and therapeutic impact. Finally, we provide a comprehensive assessment of druggable targets and suggest a stepwise patient-oriented approach for the treatment of ICI-related PM/DM.
2020
9
Solimando, Antonio G; Crudele, Lucilla; Leone, Patrizia; Argentiero, Antonella; Guarascio, Matteo; Silvestris, Nicola; Vacca, Angelo; Racanelli, Vito...espandi
Immune Checkpoint Inhibitor-Related Myositis: From Biology to Bedside / Solimando, Antonio G; Crudele, Lucilla; Leone, Patrizia; Argentiero, Antonella; Guarascio, Matteo; Silvestris, Nicola; Vacca, Angelo; Racanelli, Vito. - In: INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. - ISSN 1422-0067. - 21:9(2020), pp. 305401-305413. [10.3390/ijms21093054]
File in questo prodotto:
File Dimensione Formato  
2020 Rev ICI_Solimando_IJMS.pdf

accesso aperto

Tipologia: Versione editoriale (Publisher’s layout)
Licenza: Creative commons
Dimensione 1.7 MB
Formato Adobe PDF
1.7 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11572/386981
Citazioni
  • ???jsp.display-item.citation.pmc??? 28
  • Scopus 44
  • ???jsp.display-item.citation.isi??? 38
social impact